Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Hopes that tamoxifen could improve survival for a deadly form of fungal meningitis have been dashed by the results of a clinical trial conducted by University of Oxford researchers and published today in eLife.

Typical spherical to oval cells of Cryptococcus neoformans, with extensive capsules and a budding daughter cell © Phan Hai Trieu

The study finds that adding tamoxifen to standard antifungal treatment was no better at speeding up the clearance of fungal infection from the spinal fluid of people with meningitis. More patients who received tamoxifen had evidence of conduction disturbances in their hearts, although there was no difference in the rates of severe side effects between study groups. 

Cryptococcal meningitis is a leading cause of death in people with HIV, but also affects those without HIV, regardless of whether they are immunocompromised. Most infections are caused by a fungus called Cryptococcus neoformans (C. neoformans) and occur in low-income tropical settings. The gold-standard treatment is a combination of three drugs: flucytosine and amphotericin B initially, followed by fluconazole. Yet, even on this gold-standard therapy, a third of patients die within 10 weeks of being diagnosed. Moreover, the drug flucytosine is severely restricted by availability and cost, meaning it is rarely used where the disease burden is highest.

Co-first author Nguyen Thi Thuy Ngan, Clinician at the Department of Tropical Medicine, Cho Ray Hospital, and the Oxford University Clinical Research Unit (OUCRU), Ho Chi Minh City, Vietnam, said: 'Tamoxifen has shown antifungal activity against various yeasts in the lab; we subsequently showed that it acts synergistically with amphotericin against two-thirds of clinical Cryptococcus isolates from our archive. As a well-understood, off-patent, cheap and widely available medicine, it was a promising candidate for treating cryptococcal meningitis.'

Read the full story on the University of Oxford website

Similar stories

World Hepatitis Day: OUCRU research seeks to lower cost of treatment and improve access to care for patients with hepatitis C

Today is World Hepatitis Day. OUCRU and hospitals in Ho Chi Minh City and Hanoi have been collaborating on hepatitis C clinical trials since 2018. Our research is centred around predictive factors for selecting persons who could be successfully treated with shorter durations of antiviral therapy. OUCRU’s social science and public engagement teams are currently working with underrepresented groups to create community-led strategies to link care and treatment for populations at risk for viral hepatitis. Our aim is to have a more significant impact on the treatment strategy and access to care for patients with hepatitis C in Vietnam and worldwide in the future.

Prof Guy Thwaites co-authored WHO’s report on antibacterial agents in preclinical & clinical development

OUCRU’s Director, Professor Guy Thwaites, has recently contributed to an analysis of antibacterial agents in preclinical and clinical development by the World Health Organisation (WHO), as part of the WHO advisory group on research and development of antibacterial treatments.

Dengue Research Article Awarded The 2021 – 2022 Alexandre Yersin Prize for Outstanding Publications

OUCRU research article titled ‘Combination of inflammatory and vascular markers in the febrile phase of dengue is associated with more severe outcomes’ was recently awarded the 2021-2022 Alexandre Yersin Prize for Outstanding Publications.

OUCRU SPEAR Digital Diaries

Healthcare workers and community members in Indonesia, Nepal and Vietnam have been documenting their personal experiences of Covid-19. They have each made their own ‘digital diary’, using a range of creative tools and with technical support from the project team. These diaries form part of the SPEAR project: exploring the experiences and impacts of COVID-19 for healthcare workers and vulnerable communities.

Clinical trials for a malaria vaccine start in Mali and Indonesia

Sanaria Inc. announced that two new Phase 2 trials of its pioneering malaria vaccines have started. The first is in 6- to 10-year-old children living in Bancoumana, Mali, a malarious region of West Africa. The second is in Indonesian soldiers based in Sumatra, Indonesia. The soldiers will be deploying for six to nine months this coming August to an intensely malarious district in eastern Indonesia.

Congratulations to our new Associate Professors

Our heartfelt congratulations to Melissa Kapulu, Francis Ndungu and Emelda Okiro from KWTRP, and to Hoa Thi Ngo and Sophie Yacoub from OUCRU who have been awarded Associate Professorships